Intellia Therapeutics (NTLA) Priced

Preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology.

Health Care - Biotechnology

IPO Performance
Latest Trade $12.92 -0.39 (-2.9%)
First Day Return 22.8%
Return from IPO -26.1%
 
Intellia Therapeutics IPO News more
  • .
IPO Data
IPO File Date 04/11/2016
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.0
Deal Size ($mm) 108
 
IPO Data
IPO Date 05/05/2016
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 6.0
Deal Size ($mm) $108
 
Underwriters
more
Business Overview
We are a leading gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. We intend to leverage our leading scientific expertise, clinical development experience and intellectual property position to unlock broad therapeutic applications of CRISPR/Cas9 gene editing and develop a potential new class of therapeutic products.
We are a leading gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a recently developed biological tool known as the CRISPR/Cas9 system. We believe that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the...
more
Company Data
Headquarters Cambridge, MA
Founded 2014
Employees 61
Website www.intelliatx.com
 

Performance vs. IPO Index (IPOUSA)